The Medicines and Healthcare products Regulatory Agency (MHRA) in London is investigating the hospitalization of six men who took part in a Phase I trial of TGN1412, an immunomodulatory humanized agonistic anti-CD28 monoclonal antibody designed to treat chronic inflammatory conditions and leukemia. (BioWorld Today)
Tackling a family of proteins linked to cancer but long considered undruggable, Infinity Pharmaceuticals Inc. and Novartis AG signed a global development and commercialization deal potentially worth more than $400 million. (BioWorld Today)
Despite a rocky year that began with the Tysabri market withdrawal, Biogen Idec Inc. reported strong fourth-quarter and full-year 2005 earnings driven by robust Avonex sales and lower expenses. (BioWorld Today)
